Pharmacodynamic Analysis of Niraparib in IC Tissues

To confirm that niraparib inhibited PARP in IC tumors, tumor-bearing mice were treated as described earlier with niraparib or vehicle for 2 weeks. 25–50 mg of tumor tissue were homogenized per protocol, and lysates were used to quantify PAR (pg/ml) using a chemiluminescent enzyme-linked immunosorbent assay (ELISA) in comparison to provided standards (Trevigen, HT PARP in vivo Pharmacodynamic Assay II, #4520-096-K). PAR values were normalized across models to 100 µg of lysate.